Zimmer Biomet Q2 FY2026: revenue up 4.8%, adjusted EPS flat
Zimmer Biomet's Q2 FY2026 revenue grew 4.8% to $2.177 billion, but adjusted diluted EPS was $2.07, flat versus last year and just above the $2.0294 consensus estimate. GAAP EPS jumped 33.8% to $1.03 on lower tax and restructuring charges, while gross margin slipped to 70.8%. The company raised full-year guidance on both revenue and adjusted EPS, so the quarter supports a neutral stance: steady execution, but no acceleration in underlying profitability.
1 · Expected vs. Actual
Free preview belowGAAP diluted EPS was $1.03, up 33.8% from $0.77 a year ago, helped by a lower tax provision and fewer restructuring and acquisition charges. Adjusted diluted EPS was $2.07, exactly matching the prior-year period and edging past the $2.0294 consensus estimate by about 2.0%. Net income was $198.3 million, and the gap between GAAP and adjusted EPS remains huge—$1.04 per share—mostly from intangible asset amortization.
Q2 net sales rose 4.8% to $2.177 billion, with constant-currency growth of 4.7% and organic constant-currency growth of 4.0%. Hips (+5.0%) and S.E.T. (+6.4%) led the core categories, while Knees grew only 0.4%; Technology & Data, Bone Cement and Surgical jumped 21.1%. Gross margin slipped to 70.8% from 71.5% a year ago, so the top line grew faster than gross profit.
Log in to read 5 analyses a week for free
Create a free account to read 5 full earnings analyses each week — all five steps: expected vs. actual, guidance tracker, money flow, balance sheet and risks. Members get unlimited access.
Figures on this page come from the company's original SEC filings. The analysis is generated automatically and checked against validation rules, but may still contain errors or omissions. Not investment advice. · Generated 2026-09-17
Answers are based on the earnings release and the analysis above. Free accounts get 3 questions a week; members get 30 a day.